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Table 1 Diagnostic evaluation of neurogenic lower urinary tract dysfunction 
 
Lesion site Reported symptoms  Findings in 
cystometry 
Examples 
Suprapontine lesion Urgency, frequency, 
urgency incontinence 
Detrusor overactivity Stroke (17) 
Parkinson’s 
disease (18) 
Multiple sclerosis 
(19) 
Infrapontine suprasacral 
lesion 
Urgency, frequency, 
urgency incontinence, 
hesitancy, retention 
Detrusor overactivity, 
Detrusor-sphincter 
dyssynergia 
Multiple sclerosis 
(19) 
Multiple System 
Atrophy (20) 
Infrasacral lesion  Hesitancy, retention Detrusor 
underactivity, 
sphincter insufficiency 
Cauda equina 
syndrome (21) 
Peripheral 
neuropathy (22) 
Table 2 Situations where early referral to a specialist urology service is indicated 
Recurrent urinary tract infections 
Haematuria 
Suspicion of concomitant pathologies such as prostate enlargement or stress incontinence 
Consideration for intradetrusor injections of botulinum toxin A 
Consideration for suprapubic catheter 
Pain of presumably upper urinary tract origin 
Renal impairment 
 
Table 3 Commonly used antimuscarinic agents presented in alphabetical order 
Generic name Trade name Daily dose 
(mg) 
Frequency Selective receptor 
binding (M3:M1 
affinity ratio) 
Darifenacin 
 
Controlled 
release 
Emselex 7.5-15 od Mainly M3(9·3:1) 
Fesoterodine 
 
Controlled 
release 
Toviaz 4-8 od Not subtype 
selective 
Oxybutynin 
 
Immediate 
release 
 
Controlled 
release 
 
Transdermal 
patch 
 
 
Ditropan, 
Cystrin 
 
Lyrinel XL 
 
 
Kentera 
 
 
2.5–20 
 
 
5–20 
 
 
36 mg (3.9 
mg/24 h) 
 
 
bd–qds 
 
 
od 
 
 
One patch 
twice weekly 
 
Not subtype 
selective 
Propiverine 
 
Immediate 
release 
 
Controlled 
release 
Detrunorm 15–60 od–qds Not subtype 
selective 
Solifenacin 
 
Controlled 
release 
Vesicare 5–10 od Mainly M3(2·5:1) 
Tolterodine 
 
Immediate 
release 
 
Controlled 
release 
 
 
Detrusitol 
 
 
Detrusitol XL 
2–4 bd Not subtype 
selective 
Trospium 
chloride 
 
Immediate 
release 
 
Controlled 
release 
Regurin 20–40 bd (before 
food) 
Not subtype 
selective 
 
  
 
 
Figure 1 Algorithm for management of neurogenic lower urinary tract dysfunction in patients with 
progressive neurological disorders  
Requires permission from the BMJ Publishing Group (J Neurol Neurosurg Psychiatry 2009; 80:470-7). 
CISC, clean intermittent self-catheterisation; PVR, postvoid residual volume; UTI, urinary tract 
infection.  
 
 
 
 
